Aziz, Arkhawan (2023) Detection of Janus Kinase2 Gene Mutation and some Hematological Parameters in Polycythemic Patients /Erbil Province. Masters thesis, Koya University.
![[img]](http://eprints.koyauniversity.org/style/images/fileicons/text.png) |
Text (MSc Thesis)
MSc_DBIO_2023.pdf Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (2MB) |
Official URL: https://koyauniversity.org/
Abstract
Polycythemia vera (PV) is a clonal chronic myeloproliferative disease that causes cytokine-independent proliferation of myeloid precursors and primarily impacts the elderly. This primarily affects the erythroid lineage and causes an abnormally high number of circulating erythrocytes. Increased numbers of circulating granulocytes and platelets were also seen in many cases. The purpose of this study was to detect JAK2 mutations in patients with primary and secondary polycythemia. Additionally, erythropoietin hormone (EPO) levels were tested in polycythemic patients along with other hematological parameters were studies in 52 polycythemic patients (8 with PV and 44 blood donors). Samples were taken from patients attending Nanakaly Hospital, Directorate of Blood Bank in Erbil, and Shahid Dr. Khalid Hospital in Koya in Kurdistan region of Iraq. Sanger sequencing of JAK2 exon 14 and polymerase chain reaction (PCR) results (500 bps) showed that 3 (5.8%) polycythemic patients had heterozygous Janus Kinase2 V617F mutations, while all other samples were negative. The average of age of the study participants was 38 years, and the male participants (94.2%) were higher than the females (5.8%). The percentage of patients who have abnormal EPO for secondary polycythemia group (75%) was higher than polycythemia group (15.4%). Abnormal level of EPO was observed in patients aged between 29 to 38 (30.8%). The average of each of the hemoglobin (HGB) and hematocrit (HCT) for negative JAK2V617F was higher than the positive JAK2V617F, while the average of each of the PLT and age for negative JAK2V617F were lower than the positive JAK2V617F. Furthermore, the negative nerghila, cigarette, and alcohol had higher rates of negative JAK2V617F than their positives. Finally, most of the patients who had negative fatigue, prurtius, and headche higher rates of negative JAK2V617F than the positive JAK2V617F.
| Item Type: | Thesis (Masters) |
|---|---|
| Additional Information: | Arber, D.,A., Orazi, A., Hasserjian, R., et al. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood , 127: 2391-405. Anderson, L.,A., & McMullin ,M.,F. (2015).Epidemiology of MPN: what do we know? Curr Hematol Malig Rep. 9:340–9. Azzato, E.,M., & Bagg ,A. (2015). Molecular genetic evaluation of myeloproliferative neoplasms. Int J Lab Hematol .37(1):61–71. Ammarguellat, F., Llovera, M., Kelly, P., A., & Goffin, V. ,(2001). Low doses of EPO activate MAP kinases but not JAK2–STAT5 in rat vascular smooth muscle cells. Biochemical and biophysical research communications, 284: 1031-38. AlQahtany, FS., Algahtani, F.,H., Alshebly, MM., Madkhaly, FM., Ghandour, MK., Almalki, JH., AlOtaibi, W.,S., Salim, A., Mendoza, F.,C.,(2020). Association between cigarette & shisha smoking and the severity of polycythemia: A cross sectional study. Saudi J Biol Sci. 27(1):460-464. . AL-Rubaie, H.A., Khudeir, M.A. & Al-Bayaa, I.M., (2014). Detection of JAK2V617F tyrosine kinase mutation and estimation of serum erythropoietin in blood donors who have high hematocrit. Journal of the Faculty of Medicine Baghdad, 56(4), pp.395-400. Abrams, David, B., Glasser, Allison, M., Pearson, Jennifer, L., Villanti, Andrea C., Collins, Lauren, K., Niaura, R.,S.,(2018). Harm minimization and tobacco control: reframing societal views of nicotine use to rapidly save lives. Annu. Rev. Public Health. 39: 193–213. Aslam, H.M., Saleem, Sh., German, S., Qureshi, W.A., (2014). Harmful effects of shisha: literature review Hafiz Muhammad. Int. Arch. Med. 7. Akl, E., A., Gaddam, Ã., S., Gunukula, S., K., Honeine, R., Jaoude, P., A., & Irani, J. (2010).The effects of waterpipe tobacco smoking on health outcomes : a systematic review. Int J Epidemiol. 39(3):834-57. Aroian, K., Uddin, N. & Blbas, H., (2017). Longitudinal study of stress, social support, and depression in married Arab immigrant women. Health care for women international, 38(2), pp.100-117. Blbas, H.T.A., Aziz, K.F., Nejad, S.H. & Barzinjy, A.A., (2020). Phenomenon of depression and anxiety related to precautions for prevention among population during the outbreak of COVID-19 in Kurdistan Region of Iraq: based on questionnaire survey. Journal of Public Health, pp.1-5. Bakker, E., (2006).Is the DNA sequence the gold standard in genetic testing? Quality of molecular genetic testes assessed. Clinical chemistry, 52(4), pp.557-558. Bhatt, V.,R.(2014). Secondary polycythemia and the risk of venous thromboembolism. J. Clin. Med. Res. 6:395–397. Brusson, M., Cochet, S., Leduc, M., Guillonneau, F., Mayeux, P., Peyrard, T., Chomienne, C., Le Van Kim, C., Cassinat, B., Kiladjian, J.J. and El Nemer, W., (2017). Enhanced calreticulin expression in red cells of polycythemia vera patients harboring the JAK2V617F mutation. Haematologica, 102:241. Broséus, J., Park, J.H., Carillo, S., Hermouet, S., Girodon, F.(2014). Presence of Calreticulin Mutations in JAK2 Negative Polycythemia Vera. Blood .124, 3964–3966. Barbui, T., Thiele, J., Vannucchi, A.,M., Tefferi, A. (2014). Rethinking the diagnostic criteria of polycythemia vera. Leukemia .28: 1191-5. Barbui, T., Thiele, J., Gisslinger, H., Kvasnicka, H.M., Vannucchi, A.M., Guglielmelli, P., Orazi, A. & Tefferi, A., (2018). The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood cancer journal, 8:15. Bellucci, S. & Michiels, J.J., (2006). The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia. In Seminars in thrombosis and hemostasis, 32:381-398. Copyright© 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Butler, L.,& Maxwell, E. (2018). polycythemias/ erythrocytosis. Melbourne Pathology. 103 Victoria Parade Collingwood, Victoria 3066 | P 9287 7700. www.mps.com.au. Baker, S.J., Rane, S.,G., & Reddy, E.,P. (2007).Hematopoietic cytokine receptor signaling. Oncogen.26(47): 6724-6737. Bandaranayake, R.,M., Ungureanu, D., Shan, Y., Shaw, D.,E., Silvennoinen, O., & Hubbard, S., R. (2012). Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nature structural & molecular biology, 19(8): 754-759. Ballard, H. S. (1997). The hematological complications of alcoholism. Alcohol health and research world, 21(1), 42. Chait, Y., Condat, B., Cazals‐Hatem, D., Rufat, P., Atmani, S., Chaoui, D., Guilmin, F., Kiladjian, J.J., Plessier, A., Denninger, M.H. & Casadevall, N., (2005). Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. British journal of haematology, 129:553-560. Chauffaille, M.D.L.L., (2010). Myeloproliferative neoplasms: a review of diagnostic criteria and clinical aspects. Revista Brasileira de Hematologia e Hemoterapia, 32:308-316. Cao, M., Olsen, R.J. & Zu ,Y. (2006). Polycythemia vera. New clinicopathologic perspectives. Arch Pathol Lab Med, 130: 1126–1132. Cerquozzi, S., Tefferi, A. (2015).Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 5: e366. https://doi.org/10.1038/bcj.2015.95. Cario, H. (2005) .Childhood polycythemias/erythrocytoses: classification, diagnosis, clinical presentation, and treatment. Annals of Hematology; vol 84(3): 137-45. dos Santos, L.C., Ribeiro, JC., Silva, N.P., Cerutti, J., da Silva, MR., Chauffaille, Mde. L. (2011).Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia. Rev Bras Hematol Hemoter. 33(6):417-424. DeGennaro, L., J. (2017). Myeloproliferative Neoplasms, polycythemia vera, Essential Thrombocythemia and Myelofibrosis,Luekemia and Lymphoma society, fighting blood cancers, www.LLS.org/booklets. Ding, J., Komatsu, H., Iida, S., et al. (2009).The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity. Blood. 114(15):3325–8. Di Nisio ,M., Barbui, T., Di Gennaro, L., Borrelli, G., Finazzi, G., Landolfi, R., Leone, G., Marfisi, R., Porreca, E., Ruggeri, M., Rutjes, AW., Tognoni, G., Vannucchi, A.,M., Marchioli, R.(2007). European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP) Investigators. The haematocrit and platelet target in polycythemia vera. Br J Haematol. 136(2):249-59. Deadmond, M.A. & Smith-Gagen, J.A., (2015). Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973–2011. Journal of cancer research and clinical oncology, 141:2131-2138. Erlich, H.A., (1989) .Polymerase chain reaction. Journal of clinical immunology, 9(6), pp.437-447. Elliott, S., Pham, E. & Macdougall, I. ,C. (2008). Erythropoietins: a common mechanism of action. Experimental hematology, 36: 1573-84. Fisher, J., W. (2003). Erythropoietin: physiology and pharmacology update. Experimental biology and medicine, 228: 1-14. Foley, R. N. (2008). Erythropoietin: physiology and molecular mechanisms. Heart failure reviews, 13: 405-14. Fathima, S. J. & Khanum, F. (2017) . Mini Review Blood Res Transfus J Blood Cells and Leukocyte Culture-A Short Review, Blood Research & Transfusion Journal, 1(2). doi: 10.19080/OABTJ.2017.01.555559. Ghatak, S., Muthukumaran, R.,B., & Nachimuthu, S.,K., (2013).A simple method of genomic DNA extraction from human samples for PCR-RFLP analysis. Journal of biomolecular techniques: JBT, 24(4), p.224. Gupta, N., (2019). DNA extraction and polymerase chain reaction. Journal of cytology, 36(2). Gold, LI., Eggleton, P., Sweetwyn, MT., Van Duyn, L.,B., Grieves, M., R., Naylor, SM., Michalak, M. & Murphy-Ullrich, J.,E.,(2010). Calreticulin: non-endoplasmic reticulum functions in physiology and disease. The FASEB Journal. Mar;24(3):665-83. Gordeuk, V.R., Stockton, D.W., & Prchal, J.T., (2005).Congenital polycythemias/ erythrocytosis. Haematologica, 90(1):109-11. Ghiaur, G., & Jones, R.,J. (2019). Hematopoiesis. Springer Nature Switzerland AG. Concise Guide to Hematology.2:5-12. Glantz, S.A., Bareham, D.,W. (2018). E-cigarettes: use, effects on smoking, risks, and policy implications. Annu. Rev. Public Health. 39:215–235. Heather, J. M., & Chain, B. (2016). The sequence of sequencers: The history of sequencing DNA. Genomics, 107(1), 1–8. https://doi.org/10.1016/j.ygeno.2015.11.003 Huang, Q., Baum, L., & FU, W.L.,(2010). Simple and practical staining of DNA with GelRed in agarose gel electrophoresis. Clin Lab, 56, 149-52. Huang, L.J., Shen, Y.M. & Bulut, G.B.(2010). Advances in understanding the pathogenesis of primary familial and congenital polycythemia. British Journal of Haematology, 148: 844–52. Haroon, Z.A., Amin, K., Jiang, X., & Arcasoy ,M.O. ( 2003). A Novel Role For Erythropoietin During Fibrin-Induced Wound-Healing Response. Am. J. Pathol, 163 (3): 993–1000. Harrison, C.,N., Butt, N., Campbell, P., et al.(2014). Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia. Br J Haematol .167: 421-3. Hobbs, G.,S., Rampal, R.,K.. (2015). Clinical and molecular genetic characterization of myelofibrosis. Curr Opin Hematol . 22:177–83. Haase, V., H. (2010). Hypoxic regulation of erythropoiesis and iron metabolism. American Journal of Physiology-Renal Physiology, 299: F1-F13. He, X., Chen, Z., Jiang, Y.,et al. (2013).Different mutations of the human c-mpl gene indicate distinct haematopoietic diseases. J Hematol Oncol 6, 11 Iso, H., Date, C., Yamamoto, A., Toyoshima, H., Watanobe, Y., Kikuchi, S., koizumi, A.,Wada, Y.,kondo, T., Inaba, Y. & Tamakoshi, A. (2005). The JACC. Study Group, Smoking Cessation and Mortality from Cardiovascular Disease among Japanese Men and women: The JACC study. Am J Epidemiol. 161:170-179. Iurlo,A., Cattaneo , D., Bucelli, C. & Baldini, L. (2020). New Perspectives on Polycythemia Vera: From Diagnosis to Therapy. International Journal of Molecular Sciences. 21: 5805. doi:10.3390/ijms21165805 Ifeanyi, O. E. & Getrude Uzoma, O. (2018) ‘A Review on Erythropietin in Pregnancy’, J Gynecol Women’s Health, 8(3). doi: 10.19080/JGWH.2018.08.555740. Jameson, L., Longo, D., Hauser, S., Kasper,D.,Fauci, A., & Loscalzo, J.,(2022). Harrison's Principles of Internal Medicine: Volume 1. Macgraw-Hill. Jelkmann, W., (2004).Molecular biology of erythropoietin. Intern Med . 43: 649–659. Jelkmann, W. (2011). Regulation of erythropoietin production. The Journal of physiology, 589: 1251-58. James, C., Ugo, V., Le Couedic ,J.,P., et al. (2005). A unique clonal JAK2mutation leading to constitutive signalling causes polycythaemia vera. Nature.434(7037):1144–8. Jalowiec, KA., Vrotniakaite-Bajerciene, K., Jalowiec, J., Frey, N., Capraru, A., Wojtovicova, T., Joncourt, R., Angelillo-Scherrer, A., Tichelli, A., Porret, NA., Rovó, A.(2022). JAK2 Unmutated Polycythaemia-Real-World Data of 10 Years from a Tertiary Reference Hospital. J Clin Med.11(12):3393. Keohane, C., McMullin, M. F., & Harrison, C. (2013). The diagnosis and management of erythrocytosis. Bmj, 347. Kuter, D. J. (2013) . The biology of thrombopoietin and thrombopoietin receptor agonists’, International Journal of Hematology. Springer, 98(1), pp. 10–23. doi: 10.1007/s12185-013-1382-0. Kumar, K. R., Cowley, M. J., & Davis, R. L. (2019). Next-Generation Sequencing and Emerging Technologies. Seminars in Thrombosis and Hemostasis, 45(7), 661–673. https://doi.org/10.1055/s-0039-1688446 Kumar, V., Abbas, A. & Aster, J. (2012). Robbins Basic Pathology, ninth ed. Kawahara, R. & Shiozawa,Y. (2015). Hematopoiesis. Reference Module in Biomedical Research.1-4. Kralovics, R., Passamonti, F., Buser, A.,S., Teo, S.-S.,Tiedt, R., Passweg, J.,R.,Tichelli, A.,Cazzola, M.,Skoda, R.,C., A. (2005). Gain-of- Function Mutation of JAK2 in Myeloproliferative Disorders. N. Engl. J Med. 352, 1779–1790. Klampfl, T., Gisslinger, H., Harutyunyan, A.,S., Nivarthi, H.,Rumi, E., Milosevic, J.,D.,Them, N.,C., Berg, T., Gisslinger, B., Pietra, D., et al. (2013). Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms. N. Engl. J. Med. 369: 2379–2390. Kroll, M. H., Michaelis, L. C., & Verstovsek, S. (2015). Mechanisms of thrombogenesis in polycythemia vera. Blood reviews, 29(4): 215-221. . Klampfl, T., Gisslinger, H., Harutyunyan, A.,S., Nivarthi, H.,Rumi, E., Milosevic, J.,D.,Them, N.,C., Berg, T., Gisslinger, B., Pietra, D., et al. (2013). Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms. N. Engl. J. Med. 369(25): 2379–2390. Le Gallo, M., Lozy, F., & Bell, D. W. (2017). Next-Generation Sequencing. Advances in Experimental Medicine and Biology, 943, 119–148. https://doi.org/10.1007/978-3-319-43139-0_5. Lombardero, M., Kovacs, K., Bernd, Scheithauer, B., W. (2010). Erythropoietin: A Hormone with Multiple Functions. Pathobiology. 78:41–53. Lee, T.,S., Ma, W., Zhang, X., Kantarjian, H. & Albitar, M. (2009). Structural Effects of Clinically Observed Mutations in JAK2 Exons 13-15: Comparison with V617F and Exon 12 Mutations. BMC Struct. Biol. 9:58. Liu, C. & Hao, S.,(2018). Primary Myelofibrosis. In Chang C-C, Ohgami RS, editors. Precision molecular pathology of myeloid neoplasms. Switzerland: Spring. P. 155-179. Lacombe, C. & Mayeux, P. (1999). The molecular biology of erythropoietin. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association, 14: 22-28. Landolfi , R., Nicolazzi, MA., Porfidia, A., Di Gennaro, L. (2010). Polycythemia vera. Intern Emerg Med. 5:375–384. Lupak, O., Han, X., Xie, P., Mahmood, S., Mohammed, H. & Donthireddy, V., (2020). The role of a low erythropoietin level for the polycythemia vera diagnosis. Blood Cells, Molecules, and Diseases, 80:102355. McGinn, S., & Gut, I. G. (2013). DNA sequencing—Spanning the generations. New Biotechnology, 30(4), 366–372. https://doi.org/10.1016/j.nbt.2012.11.012 Messinezy, M., Westwood, N.B., El‐Hemaidi, I., Marsden, J.T., Sherwood, R.S. & Pearson, T.C., (2002). Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia. British journal of haematology, 117:47-53. Messinezy, M., Westwood, N.B., Woodcock, S.P., Strong, R.M. and Pearson, T.C., (1995). Low serum erythropoietin—a strong diagnostic criterion of primary polycythaemia even at normal haemoglobin levels. Clinical & Laboratory Haematology, 17:217-220. Michiels, J.J. (2013). Physiopathology, etiologic factors, diagnosis, and course of polycythemia vera as related to therapy according to William Dameshek, 1940-1950. Turk J Hematol . 30:102-111. Maddali, M., Kulkarni, U.,P., Ravindra, N., Arunachalam, A., K., Venkatraman, A., Lionel, S., Manipadam, M.,T., Devasia, A., J., Korula, A., Fouzia, N., A., & Abraham, A., (2021).Mutation profile in BCR-ABL1-negative myeloproliferative neoplasms: A single-center experience from India. Hematology/ Oncology and Stem Cell Therapy. Ma, Y., Freitag, P., Zhou, J., Brune, B., Frede, S. & Fandrey, J. (2004). Thyroid hormone induces erythropoietin gene expression through augmented accumulation of hypoxia-inducible factor-1. American Journal of Physiology- Regulatory, Integrative and Comparative Physiology, 287: R600-R07. Miller, S.,Dykes,D. & Polesky,H., (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic acids res, 16(3), p.1215. Masser, D.R., Stanford, D.R, & Freeman, W.M., (2015). Targeted DNA methylation analysis by next-generation sequencing. JoVE (Journal of Visualized Experiments), (96), p.e 52488. Mascarenhas, J., Najfeld, V., Kremyanskaya, M., Keyzner, A., Salama, M. & Hoffman, R.,(2018). Primary myelofibrosis. In Hoffman, R., Benz, EJ., Silberstein, LE., et al., editors. Hematology: Basic principles and practice 7th ed. Pennsylvania: Elsevier; p.1125-1150. McMullin, M.,F., Reilly J.,T., Campbell, P., et al. (2007). Amendment to the guideline for diagnosis and investigation of polycythaemia/ erythrocytosis. Br J Haematol .138: 821-2. Myelofibrosis Facts . The Leukemia & Lymphoma Society. (2012). Information Specialists: (800) 955 4572.www.LLS.org. Marvi, M.,M., & Lew, M.,F. (2011). Polycythemia and chorea. Handbook of Clinical Neurology, Vol. 100 :271-6. McNally, RJ., Rowland, D., Roman, E., Cartwright, R.,A. (1997). Age and sex distributions of hematological malignancies in the U.K. Hematol.Oncol. 15:173-189. Messinezy, M., Westwood, N.B., El-Hemaidi, I., Marsden, J.T., Sherwood, R.S. & Pearson, T.C. (2002) Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia. British Journal of Haematology, 117, 47–53. Malenica, M., Prnjavorac, B.. Bego, T.. Dujic, T.. Semiz, S., Skrbo, S., Gusic, A., Hadzic, A., Causevic, A.(2017). Effect of Cigarette Smoking on Haematological Parameters in Healthy Population. Med. Arch. 71: 132–136. Mohammed, S.K. & Zrari, S.A., (2020). A single developing country’s Hematology-Oncology Centre retrospective analysis of the Janus Kinase 2 V617F mutation in Philadelphia negative Myeloproliferative neoplasms. KUWAIT MEDICAL JOURNAL, 52:412-416. Mossuz, P., Girodon, F., Donnard, M., Latger-Cannard, V., Dobo, I., Boiret, N., Lecron, J.C., Binquet, C., Barro, C., Hermouet, S. & Praloran, V., (2004). Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. haematologica, 89:1194-1198. Nangalia, J., Massie, C.E., Baxter, E.J., Nice, F.L., Gundem, G., Wedge, D.C., Avezov, E., Li, J., Kollmann, K., Kent, D.G. & Aziz, A., (2013). Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. New England Journal of Medicine, 369(25):2391-2405. Nadeem, O., Gui, J. & Ornstein, L.,D. (2012). Prevalence of Venous Thromboembolism in Patients With Secondary Polycythemia. Clinical and Applied Thrombosis/Hemostasis .19(4) :363-366. Norashikin, J., Roshan, T.M., Rosline, H., Zaidah, A.W., Suhair, A.A. & Rapiaah, M., (2006). A study of serum ferritin levels among male blood donors in Hospital Universiti sains Malaysia. Southeast Asian journal of tropical medicine and public health, 37:370. Ortmann, C.A., Kent, D.G., Nangalia, J., Silber, Y., Wedge, D.,C. Grinfeld, J.,Baxter, E.,J., Massie, C.E., Papaemmanuil, E., Menon, S., et al.(2015). Effect of Mutation Order on Myeloproliferative Neoplasms. N. Engl. J. Med. 372, 601–612. Obeagu, M. (2015). A Review on Erythropoietin. International Journal of Advanced Research in Biological Sciences, 2(4): 35–47 Potula, V., & Hu, H. (1996). Relationship of Hemoglobin to Occupational Exposure to Motor vhicle Exhanst. Toxicol Ind Health. 12: 629-637. Person, T.C. & Messinezy, M., (1996). Investigation of patients with polycythemia, 72: 519-24. Purandare, A. V., Lorenzi, M. V. & Lombardo, L. J. (2010). Chapter 13: Janus Kinase (JAK2) Inhibitors for the Treatment of Myeloproliferative Neoplasm (MPN). Annual Reports in Medicinal Chemistry. v. 45:210-227. Polycythemia Vera Facts. The Leukemia & Lymphoma Society (2015). Information Specialists:800.955.4572. www.LLS.org. formation Pikman, Y., Lee, B.,H., Mercher, T., McDowell, E., Ebert, B.,L.,Gozo, M., Cuker, A.,Wernig, G., Moore, S., Galinsky, I., et al., (2006). MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia. PLoS Med. 3: 1140–1151. Passamonti, F., Rumi, E., Pungolino, E., Malabarba, L., Bertazzoni, P., Valentini, M., et al. (2004).Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 117(10):755–61. https://doi. org/10.1016/j.amjmed.2004.06.032. Prchal, J.,T. (2003) .Classification and molecular biology of polycythemias (erythrocytoses) and thrombocytosis. Hematol Oncol Clin North Am 17:1151. Putter , J., S. & Seghatchian, J. (2021). Polycythaemia vera: molecular genetics, diagnostics and therapeutics. International Society of Blood Transfusion. Vox Sanguinis . 116, 617–627. Patel, A., B., Franzini, A., Leroy, E., Kim, S.,J., Pomicter, A., D., Genet, L., Xiao, M., Yan., D., Ahmann, J., M., Agarwal, A., M., & Clier, P. (2019). JAK2ex 13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera. Blood, 134(26), 2388-2398. Pardanani, A.D.,Levine, R.,L., Lasho, T., Pikman, Y., Mesa, R.A.,Wadleigh, M., Steensma, D.P.,Elliott, M.,A., Wolanskyj, A.,P., Hogan, W.J., et al. (2006).MPL515 Mutations in Myeloproliferative and Other Myeloid Disorders: A Study of 1182 Patients. Blood . 108, 3472–3476. Rohland, N., Glocke, I., Aximu-Petri, A., & Meyer, M., (2018). Extraction of highly degraded DNA from ancient bones, teeth and sediments for high-throughput sequencing. Nature protocols, 13(11),pp.2447-2461. Regimbeau, M., Mary, R., Hermetet, F., & Girodon, F. (2022). Genetic Background of Polycythemia Vera. Genes, 13, 637. https://doi.org/10.3390/genes13040637 Rieger, M.,A., & Schroeder, T. (2012). Hematopoiesis. Cold Spring Harbor Perspective Biology.4: 1-17. Ruggeri, M., Tosetto, A., Frezzato, M., & Rodeghiero, F. (2003). The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. Ann. Intern. Med. 139: 470–475. Rosso V, Petiti, J., Bracco, E., Pedrola, R., Carnuccio, F., Signorino, E., Carturan, S., Calabrese, C., Bot-Sartor, G., Ronconi, M., Serra, A., Saglio, G., Frassoni, F., Cilloni, D.(2017). A novel assay to detect calreticulin mutations in myeloproliferative neoplasms. Oncotarget .8(4):6399-6405. Rumi, E., Pietra, D., Ferretti, V., Klampfl, T., Harutyunyan, A.S., Milosevic, J.D., Them, N.C., Berg, T., Elena, C., Casetti, I.C. & Milanesi, C., (2014). JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood, The Journal of the American Society of Hematology, 123:1544-1551. Slatko, B. E., Gardner, A. F., & Ausubel, F. M. (2018). Overview of Next-Generation Sequencing Technologies. Current Protocols in Molecular Biology, 122(1), e59. https://doi.org/10.1002/cpmb.59 Sofi, JS., Hidayat, JH., (2022). Molecular Screening of Exon 12 of Janus Kinase 2, Exon 9 of Calreticulin Genes in Polycythemia Vera Patients with Unmutated Janus Kinase 2 V617F. Indian Journal of Pharmaceutical Sciences, 84(3):27-31. Scott, L.,M., Tong ,W., Levine ,RL., et al., (2007).JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 356(5):459–68. Scott, L.M., (2011). The JAK2 exon 12 mutations: a comprehensive review. American journal of hematology, 86:668-676. Spivak, JL.( 2018).Polycythemia Vera. Curr Treat Options Oncol. 19(2):12. Spivak, J.L. & Silver, R.T., (2008). The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood, 112:231. Srour, S.A., Devesa, S.S., Morton, L.M., Check, D.P., Curtis, R.E., Linet, M.S. & Dores, G.M., (2016). Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001–12. British journal of haematology, 174:382-396. Sirén ,A.L., Fratelli, M., Brines, M., Goemans, C., Casagrande, S., Lewczuk, P., Keenan, S., Gleiter, C., Pasquali, C., Capobianco, A., Mennini, T., Heumann, R., Cerami, A., Ehrenreich, H., Ghezzi, P. (2001). Erythropoietin Prevents Neuronal Apoptosis After Cerebral Ischemia And Metabolic Stress. Proc Natl Acad Sci USA ,98 (7): 4044–4049. Stein, B.,L., Oh, S.,T.,Berenzon, D., Hobbs, G.,S., Kremyanskaya, M., Rampal, RK., Abboud, C.,N., Adler, K., Heaney, M.,L., Jabbour, E.,J., Komrokji, R.,S., Moliterno, R.,S., Ritchie, E., K., Rice, L., Mascarenhas, J.,& Hoffman, R. (2015). Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. American Society of Clinical Oncology. PP.1-6 . DOI: 10.1200/JCO.2015.61.6474. Smith, C. (2003). Hematopoietic Stem Cells and Hematopoiesis. Cancer Control, 10(1): 9-16. Sekhar, M., McVinnie, K., Burroughs, AK.(2013).Splanchnic vein thrombosis in myeloproliferative neoplasms. Br J Haematol. 162(6): 730–47. https://doi.org/10.1111/bjh.12461. Silverstein, M.N. (2016). Relative and absolute polycythemia, Postgraduate Medicine, 81(5): 285-288. Sassaki, MG., Souza, CA., Siciliano, RF., et al. (2000). Polycythemia vera in a patient with the human immunodeficiency virus: a case report. Braz J Infect Dis 4: 204–207. Saint ,S. & Chopra, V. (2018). Polycythemia, Oxford University Press, Print ISBN-13: 9780190862800, PP.1-5. Steensma, D.,P., Bejar, R., Jaiswal ,S,. et al., (2015). Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood .126:9-16. Sadiq, K., Al., Badr, J.,A., Graiti, T., A.(2019). Effects of Hookah Smoking on Blood Contents and Some Organ Functions of Men Body. Phys.: Conf. Ser. 1234 012077. Sung, SY., Chang, YC., Wu, HJ., Lai, HC.(2022). Polycythemia-Related Proliferative Ischemic Retinopathy Managed with Smoking Cessation: A Case Report. Int J Environ Res Public Health.30:19(13):8072. Shawky, A., M., (2020) Smoker’s Polycythemia: Is It a Cardiovascular Risk?. Cardiol Vasc Res. 4(4): 1-5. Shi, J., Yuan, B. Hu, W. & Lodish, H. (2016). JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways, Exp Hematol ,44 (11) :1044–1058.e5. Shih, H., Wu,C., Lin, Sh. (2018). Physiology and pathophysiology of renal erythropoietin-producing cells. Journal of the Formosan Medical Association . 117, 955-963. Shendure, J., Balasubramanian, S., Church, G. M., Gilbert, W., Rogers, J., Schloss, J. A., & Waterston, R. H. (2017). DNA sequencing at 40: Past, present and future. Nature, 550(7676), 345–353. https://doi.org/10.1038/nature24286 Tefferi, A. (2003). Polycythemia vera. A Comprehensive Review and Clinical Recommendate lon s. Mayo clin Proc. 78:174-194. Tefferi, A. 2007, JAK2 Mutations in Polycythemia Molecular Mechanisms and Clinical Applications. The New England Journal of Medicine,365(5),PP.444-445. Tefferi , A., Vannucchi, M.,A. & Barbui, T. (2021). Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia .35:3339–3351; https://doi.org/10.1038/s41375-021-01401-3 Tefferi, A. & Barbui ,T. (2015). Essential thrombocythemia and polycythemia vera: focus on clinical practice. Mayo Clin Proc .90:1283–93. Tefferi, A., & Barbui, T. (2020).Polycythemia Vera and Essential Thrombocythemia: 2021 Update on Diagnosis, Risk-stratification and Management. Am. J. Hematol. 95:1599–1613. Tefferi, A. & Pardanani, A. (2015). Myeloproliferative neoplasms: a contemporary review. JAMA Oncol .1:97–105. Tefferi, A., Lasho, T.,L., Guglielmelli, P., Finke, C.,M.,Rotunno, G., Elala, Y., Pacilli, A., Hanson, C.,A., Pancrazzi, A., Ketterling, R.,P., et al., (2016).Targeted Deep Sequencing in Polycythemia Vera and Essential Thrombocythemia. Blood Adv. 1: 21–30. Tefferi, A., Wassie, EA., Guglielmelli, P., Gangat, N., Belachew, A.,A., Lasho, TL., et al.(2014). Type 1 versus Type 2 CALReticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol. 89:E121–4. Tefferi, A., Lasho, T.,L., Finke, C., Belachew, A.,A., Wassie, E.,A., Ketterling, RP., et al.(2014) Type I vs Type 2 CALReticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. Leukemia.28:1568–70. Takenaka, K., Shimoda, K.,& Akashi, K. (2018). Recent advances in the diagnosis and management of primary myelofibrosis. Korean J Intern Med. 33(4):679-690. doi: 10.3904/kjim.2018.033 Thom, C.,S., Dickson, C.,F., Gell, D.,A., Weiss, M.,J.(2013). Hemoglobin variants: biochemical properties and clinical correlates. Cold Spring Harb Perspect Med. 1:3(3):a011858. Um, M., & Lodish, H. F. (2006). Antiapoptotic effects of erythropoietin in differentiated neuroblastoma SH-SY5Y cells require activation of both the STAT5 and AKT signaling pathways. Journal of Biological Chemistry, 281:5648-56. Verma, A., Kambhampati, S., Parmar, S., Platanias, LC. (2003). Jak family of kinases in cancer. Cancer Metastasis Rev. 22:423-34. Vannucchi, A., M., Guglielmelli, P. (2013). JAK2 Mutation-Related Disease and Thrombosis. Semin Thromb Hemost .39:496–506. Vannucchi, A.,M., Pancrazzi, A., Bogane, C., Antonioli, E. and Guglielmelli, P.,(2006). A quantitative assay for JAK2V167F mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia, 20(6):1055-1060. Wu, Z., Zhang, X., Xu, X., Chen, Y., Hu,T., Kang, Z., Li, S., Wang, H., Liu, W., Ma., X. & Guan, M., (2014). The mutation profile of JAK2 and CARL in chines Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Journal of hematology & oncology. 7(1): 1-10. Wilkins, B.,S., Erber, W.,N., Bareford, D., et al.,(2008). Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood .111: 60-70. Wilks, AF.,2008, The JAK kinases: not just another kinase drug discovery target. Semin Cell Dev Biol ,19,pp.319–28. Xie, M., Lu, C., Wang, J., et al.,(2014). Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat.Med. 20:1472-1478. Xia, D. & Hasserjian, R.P. (2016). Molecular testing for JAK2, MPL, and CALR in myeloproliferative neoplasms. Am J Hematol .91 (12) :1277–1280. Xu, X., Zhang, Q., Luo, J., Xing, S., Li, Q., Krantz, S.B., Fu, X. & Zhao, Z.J., (2007). JAK2V617F: prevalence in a large Chinese hospital population. Blood, 109:339-342. Yadav, S., Chaudhary, J., Kumar, N., Kannauje, P.K., Kumar, K., Bhattnagar, R. & Tiwari, R., (2018). Distribution of ABO and Rh blood group in myeloproliferative diseases. Acta Medica International, 5:39. Yamaoka, K., Saharinen, P., Pesu, M., Holt, V., E., Silvennoinen, O., & O'Shea, j. j. (2004). The janus kinases (jaks). Genome biology. 5(12): 1-6. |
| Subjects: | Q Science > QH Natural history > QH301 Biology |
| Divisions: | Faculty of Science and Health > Department of Biology > M.Sc. Thesis |
| Depositing User: | Mr. Rebwar Mohammed Jarjis |
| Date Deposited: | 30 Oct 2023 09:55 |
| Last Modified: | 30 Oct 2023 09:55 |
| URI: | http://eprints.koyauniversity.org/id/eprint/423 |
Actions (login required)
 |
View Item |
